Latest Financial Results
Q3 2020
Quarterly Results
September 30, 2020
Stock Quote
Titan Pharmaceuticals, Inc.
Nasdaq: TTNP
Volume
Day Low/High
52 Week Low/High
Company Overview
Titan is a specialty pharmaceuticals company that develops therapeutics for select chronic diseases utilizing its innovative, long-term, continuous drug delivery platform, ProNeura. The company's lead product is Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction. On May 26, 2016, the U.S. Food and Drug Administration approved Probuphine for the long-term maintenance treatment of opioid dependence in stable patients receiving a low to moderate daily dose of oral buprenorphine therapy. Probuphine is the first marketed product to provide maintenance treatment of opioid addiction continuously for six months following a single administration procedure.
Officers & Directors
Marc Rubin, MD
Executive Chairman
Dr. Rubin has served as Titan's Executive Chairman of the Board of Directors since 2009, after previously holding the position of CEO. Prior to joining Titan, Dr. Rubin was Head of Global Research and Development for Bayer Schering Pharma,…
View Full Bio
Kate DeVarney, Ph.D.
President and Chief Operating Officer
Dr. DeVarney joined Titan in January 2007 to lead the clinical development and medical affairs group and currently serves as Titan's Executive Vice President and Chief Development Officer. Before joining Titan, she was a Senior Director…
View Full Bio
Marc Rubin, MD
Executive Chairman
Dr. Rubin has served as Titan's Executive Chairman of the Board of Directors since 2009, after previously holding the position of CEO. Prior to joining Titan, Dr. Rubin was Head of Global Research and Development for Bayer Schering Pharma,…
View Full Bio
Sunil Bhonsle, MBA
Director
Sunil Bhonsle has served as Titan's President since 2009, after previously holding the positions of Executive Vice President and Chief Operating Officer. Prior to joining Titan, Mr. Bhonsle served for 20 years at Bayer Corp., where he was…
View Full Bio
Kate DeVarney, Ph.D.
President and Chief Operating Officer
Dr. DeVarney joined Titan in January 2007 to lead the clinical development and medical affairs group and currently serves as Titan's Executive Vice President and Chief Development Officer. Before joining Titan, she was a Senior Director…
View Full Bio
Joseph A. Akers
Audit Committee
Mr. Akers has served as president of Bayer's hematology/cardiology business, where he oversaw the core of Bayer's specialty pharmaceuticals development, with significant products in hematology and specialty cardiology. Mr. Akers also…
View Full Bio
M. David MacFarlane, PhD
Audit Committee; Corporate Governance and Nominating Committee
Dr. MacFarlane has been a Director of Titan Pharmaceuticals since May 2002. Dr. MacFarlane served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. from 1989 until his retirement in August 1999. Prior to…
View Full Bio
James R. McNab, Jr.
Corporate Governance and Nominating Committee
Mr. McNab, an entrepreneur experienced in building and growing companies, is co-founder and chairman of Curis, a publicly traded oncology company that partnered with Roche to develop and commercialize a first-in-class hedgehog inhibitor…
View Full Bio
Scott Smith
Director
In his current role as president of global inflammation and immunology, Mr. Smith leads a team of over 1,300 people and is responsible for the inflammation and immunology portfolio, including all global commercial, clinical development,…
View Full Bio